Moderna’s vaccine is designed to target H5 and H7 avian influenza viruses. HealthDay News — The U.S. Department of Health and Human Services (HHS) is awarding the pharmaceutical company Moderna $590 ...

Moderna (MRNA) cut its 2025 forecast by $1 billion Monday, citing weak demand for its newest vaccine as well as slow sales for its COVID-19 vaccine. The company now expects $1.5 billion to $2 ...

There are currently three vaccine candidates moving through the clinical pipeline in human trials right now, and the furthest along is Moderna, which has developed a norovirus vaccine with the ...

There is no antiviral treatment for the miserable but thankfully short-lived illness, and no vaccine—yet. But scientists at Moderna are in the late stages of testing what could be the first such ...

While the U.S. already has vaccines against H5 viruses in its Strategic National Stockpile, they are based on older technology. HealthDay News — The U.S. Department of Health and Human Services (HHS) ...

Shares of vaccine companies fell after a Senate panel voted to advance Robert F. Kennedy Jr.'s nomination to lead the ...

The virus has also been identified in bat species from a number of other countries, including Cambodia, Ghana, Indonesia, Madagascar, the Philippines ... completes. Moderna's mRNA vaccine platform ...

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial ...

In 2023, the company commenced a Phase I/II trial to assess the immune response and safety of pandemic influenza vaccine. Credit: pcruciatti/Shutterstock. Moderna is set to receive $590m in funding ...

Moderna Inc. shares plunged after the company slashed its sales forecast for this year as it struggles with slow demand for its Covid and RSV vaccines. The Cambridge, Massachusetts-based company ...

MSD and Moderna’s individualised cancer vaccine mRNA-4157 has shown impressive efficacy in a phase 2b trial in skin cancer melanoma, leaving the partners speculating about a possible regulatory ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business ...